/
IXHL
$3.62+$0.20 (+5.85%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$40.9M
12M shares
52-week range
$2.49 – $49.80
2% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
ADRC
Borrow rate
8.74%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-442.78
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.0M | $1.2M | $599.7K | $1.9M | $785.2K | $0 | $12.0K | $86.0K |
| Cost of revenue | $522.8K | $583.2K | $446.5K | $913.3K | $6.3K | $0 | $103.0K | $246.0K |
| Gross profit | $487.0K | $597.3K | $153.2K | $987.0K | $778.8K | $0 | $12.0K | −$160.0K |
| Gross margin | 48.2% | 50.6% | 25.5% | 51.9% | 99.2% | — | 100.0% | -186.0% |
| R&D | $0 | $0 | $0 | $4.8M | $5.4M | $9.5M | $19.3M | $10.7M |
| Operating income | −$3.2M | −$2.8M | −$4.1M | −$11.4M | −$10.2M | −$20.5M | −$30.0M | −$23.8M |
| EBITDA | −$3.1M | −$2.7M | −$4.1M | −$11.4M | −$16.5M | −$20.4M | −$27.7M | −$23.5M |
| Net income | −$2.9M | −$2.7M | −$4.7M | −$11.4M | −$14.9M | −$73.5M | −$18.5M | −$46.9M |
| Net margin | -291.2% | -230.7% | -776.6% | -599.3% | -1898.0% | — | -153825.0% | -54517.4% |
| EPS (diluted) | -1.56 | -0.74 | -0.69 | -1.40 | -1.51 | -14.31 | -3.42 | -40.80 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $700000 | $-1.56 | $-1.56–$-1.56 | 1 |
| 2027 | $40M | $-1.46 | $-1.46–$-1.46 | 1 |
| 2028 | $53431 | $-1.85 | $-1.85–$-1.85 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$8.19
Price
$3.62
Implied upside
+126%
Peer comparison
Incannex Healthcare Limited American Depositary Shares
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.
www.incannex.com.au- Employees
- 12
- IPO / List date
- Feb 25, 2022
- HQ
- NORWEST NSW
Held by traders on TradeandTell
No one on the platform currently holds IXHL.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in IXHL as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2026-02-27 | 1-for-30reverse |
Recent trades on TradeandTell
No one on the platform has traded IXHL yet.
